Fig. 1

MEKi reduces viral load in RV2 challenged AECs but not those challenged with RSVA2. a Total RNA was extracted from AECs 24h p.i. (MOI 0.1) and then reverse-transcribed using RV or RSV-specific primers. RV2 or RSVA2 vRNA copy number was quantified by RT-qPCR. b RV2 live virus containing supernatants were collected at 24h p.i. and were used to infect permissive H1-HeLa cells. 50% CPE was determined using viral ToxGlo™ kit. c Cytotoxicity analysis of LDH release in the supernatants of AECs pretreated with DMSO, MEKi, or anti-IFN-β antibody for 1h followed by infection with or without RV2 or RSVA2 or UV-inactivated viruses for 24h (MOI 0.1). d Total RNA was extracted from AECs infected with RV2 for 2-6h (MOI 0.1) and mRNA was reverse transcribed using oligo (dT) primers. RV2 copy number was quantified by RT-qPCR. e RV2 copy number was quantified by RT-qPCR using total RNA extracted from H1-HeLa cells 24h p.i. (MOI 0.1). Each symbol () represents a donor and the horizontal bars represent the grand median in a, c, and d (n = 6). Data are presented as median and error bars represent 95% confidence interval (n = 6). Three independent experiments in e. Statistical analysis was performed with the Wilcoxon signed-rank test. *p < 0.05 indicates statistical significance